DRAXIS Appoints New Head Of Investor Relations.Business Editors MISSISSAUGA, Ontario--(BUSINESS WIRE)--May 28, 2001 DRAXIS Health Inc. (Nasdaq:DRAX) (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :DAX) announced today that it has appointed Jerry Ormiston as Executive Director of Investor Relations Investor relations The process by which the corporation communicates with its investors. , effective immediately. Mr. Ormiston will report to Dr. Martin Barkin, President and Chief Executive Officer of DRAXIS Health, and will serve as a member of the DRAXIS executive team. "Building and maintaining effective relationships with the capital markets as we move toward sustainable profitability is an important part of generating shareholder value," stated Dr. Martin Barkin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of DRAXIS. "We believe that Jerry Ormiston's addition to our team at this time will significantly contribute toward that objective. His long term experience in our industry, together with his recognized accomplishments in investor relations will serve us well as we move forward to build our businesses both in Canada and the United States The United States and Canada share a unique legal relationship. U.S. law looks northward with a mixture of optimism and cooperation, viewing Canada as an integral part of U.S. economic and environmental policy. ." Prior to DRAXIS, Jerry Ormiston was a senior consultant specializing in healthcare at a leading Canadian Canadian (kənā`dēən), river, 906 mi (1,458 km) long, rising in NE New Mexico. and flowing E across N Texas and central Oklahoma into the Arkansas River in E Oklahoma. investor relations firm and previously was manager of investor relations for Allelix Biopharmaceuticals. Additional healthcare and biotechnology experience has included management positions in business development, marketing, production and regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: DRAXIS Health Inc. is a diversified diversified (di·verˑ·s specialty pharmaceutical company with operations in three specialty markets: radiopharmaceuticals (DRAXIMAGE), contract manufacturing (DRAXIS Pharma), and pharmaceutical sales and marketing (DRAXIS Pharmaceutica). Except for historical information, this news release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the US Securities and Exchange Commission and Canadian securities authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion